Advanced Enzyme Technologies share price today

Advanced Enzyme Technologies Ltd's share price was ₹278.40 at the close on 4 November 2026. It has been falling for 10 weeks. That is 9.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹248 and ₹377, and at that close it sat 23% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Advanced Enzyme Technologies Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 20 weeks running.

Over the last 10 years the share price moved −2% while the NIFTY 500 moved +201%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 June 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) cut their stake for 5 quarters in a row, revenue up on a year earlier for 8 quarters in a row and best operating margin in 10 quarters.

1. Indian funds and insurers (DIIs) cut their stake for 5 quarters in a row

   From 8.5% to 1.9% of the company by the September 2026 quarter.

2. Revenue up on a year earlier for 8 quarters in a row

   In the September 2026 quarter revenue was ₹215 crore, +16.2% on a year earlier.

3. Best operating margin in 10 quarters

   Operating margin was 34% in the September 2026 quarter, against 33% a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), Advanced Enzyme Technologies reported revenue of ₹215 crore, up 16.2% from ₹185 crore a year earlier, and a profit of ₹51.0 crore, up 13.3% from ₹45.0 crore.

Advanced Enzyme Technologies results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 12 August 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Advanced Enzyme Technologies closed at ₹278.40 on 4 November 2026, down 10.3% from ₹310.40 a year earlier (7 November 2025) and down 23.5% over five years. Its highest weekly close since August 2016 was ₹538.05 on 20 September 2024.

Advanced Enzyme Technologies share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

542 weekly closes from 5 August 2016 to 4 November 2026.

4 Nov 2026: Advanced Enzyme Technologies closed at ₹278.40, up 5.6% on the week and up 1.5% on the month. Results for July to September 2026: Revenue up 16.2% and profit up 13.3% on a year earlier.

Earlier

• 12 Aug 2026: Advanced Enzyme Technologies held its results call for April to June 2026. Management guided: FY27 consolidated revenue growth in double digits; US business growth not expected to exceed approximately 8-10%, with approximately 8% by year-end.
• 24 Jul 2026: ex-date for a dividend of ₹1.35 a share.

Advanced Enzyme Technologies paid ₹1.35 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.48% at the ₹278.40 close on 4 November 2026. The last was a dividend of ₹1.35 a share, ex-date 24 July 2026.

Advanced Enzyme Technologies dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Advanced Enzyme Technologies Ltd paid out 36% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 12 August 2026, Advanced Enzyme Technologies' management guided: FY27 consolidated revenue growth in double digits; US business growth not expected to exceed approximately 8-10%, with approximately 8% by year-end.

“We are trying to revamp and change our business model in such a way that we have sustained growth while our margins remain intact.”Mukund Kabra, on the call for April to June 2026

What management guided

• Incremental sales reversal expected to normalise in July to September 2026 after shipment delivery.
• Operating margin expected to return to approximately 30% for FY27 and remain within 30-32%.
• Biocatalysis expected to deliver good growth in H2FY27; protein-hydrolysis sales to develop across subsequent quarters.
• Approximately ₹123 crore consolidated capital spending, including ₹20 crore normal capital spending and ₹50 crore R&D; capacity spending may begin after next-quarter review and the R&D facility may become functional next quarter.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 12 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

Consolidated operating margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below ₹500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds.

The main risks

• US market structural weakness and tariff absorption: US revenue constrained by tariffs and consumer softness; FY27 US growth guided at 8-10%. ✓ fact
• Operating margin compression from input and energy costs: April to June 2026 operating margin compressed to 27%; FY27 recovery to 30-32% dependent on operational leverage. ⚠ estimate

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Advanced Enzyme Technologies reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Q2 revenue print: verify sales-reversal normalisation and whether the robust pipeline produces the expected momentum improvement.

Advanced Enzyme Technologies is not on any of our India lists this week.

Advanced Enzyme Technologies Ltd earned ₹51.0 Cr of net profit in the Sep 2026 quarter, +13.3% on the same quarter a year earlier. Full-year FY26 profit was ₹174 Cr. Over 10 years profit has grown 8.5% a year on average. That is 23.7% of the quarter's revenue. The same quarter a year earlier earned ₹45.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹174 Cr (+29.9% on the year before).

Why profit moved: revenue changed +16.2% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +21.9% and revenue +10.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY27-Q1. revenue ₹192 Cr and profit ₹39 Cr as reported.

FY27-Q2. revenue ₹215 Cr and profit ₹51 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Advanced Enzyme Technologies Ltd reported ₹215 Cr of revenue in the Sep 2026 quarter, +16.2% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 10 years it has grown 9.8% a year on average. The last full year, FY26, came in at ₹746 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹782 Cr.

FY26 revenue was ₹746 Cr, +17.1% on the year before.

Recent pace: the last four quarters grew +10.7% on average, against 9.8% a year over the longer run, so this year is growing at about the same pace as its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.6%, against +12.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +17.9%, against +12.8% a year (accelerating).

FY27-Q1. revenue ₹192 Cr and profit ₹39 Cr as reported.

FY27-Q2. revenue ₹215 Cr and profit ₹51 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Advanced Enzyme Technologies Ltd's operating margin was 34.0% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 21.0% and 47.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +1.1 percentage points on the year while gross margin changed −2.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY27-Q1. revenue ₹192 Cr and profit ₹39 Cr as reported.

FY27-Q2. revenue ₹215 Cr and profit ₹51 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Over the last 3 years, 99% of Advanced Enzyme Technologies Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹157 Cr of operating cash against ₹174 Cr of profit. After ₹82.0 Cr of spending on assets, ₹75.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 99% of profit came in as cash: the cash cycle got 22 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 1.6× depreciation over three years. The next section checks what that spending is building.

Advanced Enzyme Technologies Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 331 days in FY26, down from 353 days in FY21. It spent ₹184 Cr on assets over the last 3 years. Customers take 71 days to pay, and stock sits for 335 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. Consolidated capex plan includes ₹50 Cr for R&D expansion in FY27 (). Modernized facility triples development bandwidth for 15-20 active pipeline molecules. Confidence capped at 0.40 due to timeline slippages ().

At FY26 sales of ₹746 Cr, each day of that cycle ties up about ₹2.0 Cr, so roughly ₹677 Cr is tied up in the business at any time.

FY26: customers took 71 days to pay and stock sat for 335 days, about 11.0 months of sales sitting as stock, for a full cycle of 331 days, shorter than FY21's 353.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 335 days. Customers pay about 71 days after that. Suppliers are paid at 76 days. Together that makes the 331-day cycle.

Spending on assets: ₹184 Cr over the last 3 years, against ₹112 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹51.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Advanced Enzyme Technologies Ltd's P/E is 19.2×, near the low end of its own history: it has been lower only 16% of the time. Its usual P/E (the middle reading) is 27.6×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹15.26.